Slide 1: Investor Presentation Q2FY19
Investor Presentation Q2FY19 05-11-2018
Slide 2: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results t
Slide 3: Update on our key FY19 priorities and challenges
Update on our key FY19 priorities and challenges Key Priorities India: Growth & Therapy US: Launches & 1 Strengthening1 2 Ramp-up 3 US Filings Ramp-up Strong market beating performance across 7 approvals in Q2 including 5 ANDAs filed in Q2 key therapeutic areas Atazanavir, Diclofenac gel On-track fo
Slide 4: Financial Performance – Q2FY19
Financial Performance – Q2FY19 Revenues INR 4,012 Cr EBITDA 18.8% to sales Q2 FY19 (Consolidated) Revenue1 Break-up Actuals Global API, Others, vs Q2 FY 18 (Rs Cr) 4% 2% Europe, 3% Total Revenue from 4,012 -2% Operations Emerging a) Domestic Sales 1,666 -1% Mkts, 12% India, 41% b) Int’l Sales 2,282
Slide 5: EBITDA Build-up
EBITDA Build-up INR Cr Q2FY19 Q2FY18 Q1FY19 Profit Before Tax 509 573 620 Add: Finance Costs 44 42 35 Depreciation, Amortisation & impairment Expense 282 302 241 Less: Finance, investment & Divestitures related income 82 113 170 EBITDA 753 804 726 EBITDA % to Sales 18.8% 19.7% 18.4% Financial number
Slide 6: India (Rx + Gx) Sales
India (Rx + Gx) Sales Q2 Y-o-Y H1 Y-o-Y Rs Cr Rs Cr 3500 1800 9% 3187 1645 1644 2915 1600 3000 1400 2500 Higher base in 1200 1000 2000 GST adjusted H1 Q2FY18 due to GST led inventory 800 1500 Growth at 13% 600 re-stocking 1000 400 200 500 0 0 Q2 FY 18 Q2 FY 19 H1 FY18 H1 FY19 Key Business Highlights
Slide 7: North America: Ramp-up across key DTM launches drives quarterly growth
North America: Ramp-up across key DTM launches drives quarterly growth with strong improvement in margins Q2 Y-o-Y $ Mn Q2FY191 40% 25% 96 12% 108 Contribution from new of Q2FY19 1 products launches in of Q2FY19 DTM2 Total US last 12 months Revenues Revenues +900bps Q2 FY18 Q2 FY19 Significant Gross
Slide 8: ANDA Portfolio & Pipeline (As on 30th Sept 2018)
ANDA1 Portfolio & Pipeline (As on 30th Sept 2018) Total 161 24 71 256 ANDAs 180 ANDA Portfolio 160 140 38 120 100 53 80 9 5 60 21 40 2 61 3 20 2 43 11 0 8 Approved ANDAs Tentatively Approved ANDAs Under Approval ANDAs 2 1 Does not include Vet product ANDAs Cipla Ltd PEPFAR Invagen Partnered ANDAs 2
Slide 9: SAGA: South Africa, Sub-Saharan Africa and Cipla Global Access
SAGA*: South Africa, Sub-Saharan Africa and Cipla Global Access Q2 Y-o-Y H1 Y-o-Y $ Mn $ Mn Q2 Impacted by lower tender offtake in Global Access 104 63 74 36 81 156 158 72 South Africa Others Q2 FY18 Q2 FY19 H1 FY18 H1 FY19 Key Business Highlights1 As per IQVIA (IMS) MAT Aug’18, South Africa busin
Slide 10: EM, Europe and API
EM, Europe and API Emerging Markets Europe API $ Mn $ Mn $ Mn 80 71 25 35 33 67 23 70 -5% -14% 20 30 -26% 60 20 24 25 50 15 20 40 30 10 15 20 10 10 5 5 0 0 0 Q2 FY18 Q2 FY19 Q2 FY18 Q2 FY19 Q2 FY18 Q2 FY19 Biosimilars franchise in the EM: Late stage discussions on-going for various Continued mom
Slide 11: Some emerging challenges for the next quarters
Some emerging challenges for the next 2 quarters Emerging Challenges Sanctions to impact reported performance in certain parts of the business Capacity balancing: Currently engaged in capacity balancing in certain specific categories at our plants which will have a short-term impact Commodity & Crud
Slide 12: Thank you
Thank you Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Naveen Bansal Investor.Relations@cipla.com For more information please visit www.cipla.com Investor Presentation: Q2FY19 12